Search company, investor...
NevisQ company logo


Founded Year



Incubator/Accelerator | Alive

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+20 points in the past 30 days

About NevisQ

nevisQ develops baseboards that capture entire spatial geometries and identify objects and people within a room.

Headquarters Location

Dennewartstrasse 25-27

Aachen, D-52068,


+49 241 927884010

Missing: NevisQ's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NevisQ's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing NevisQ

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NevisQ is included in 1 Expert Collection, including Senior Care.


Senior Care

404 items

Latest NevisQ News

EIT Health Germany will fund six promising start-ups

Nov 13, 2017

Brief description: nevisQ develops an intelligent sensor system for discrete room monitoring in nursing care facilities in order to relieve the nursing staff and to increase the quality of care. The solution is based on infrared sensor strips, which create a two-dimensional image of a room and recognize objects as well as persons in the room. Machine learning algorithms are used to interpret movements and situations so that for example falls can be clearly identified. The infrared sensor strips can be installed in or above the basebaords a few centimeters over the ground, making them very discreet and easy to install. As soon as the sensor system detects a critical situation of a nursing home resident, such as a fall, the nursing staff is immediately notified to help the fallen person. The advantage here is that the person in need of care does not have to carry a device, such as an emergency button, or has to call actively for help himself. The solution gives nursing homes a competitive advantage and can therefore also increase profitability. At the same time, the nursing homes and the health insurance companies can save costs, for example by a smaller number of falls with serious consequences and a more efficient care work with fewer sick days of the workforce. Project Title: HealthLab MRN 2025 Name of Organisation: OptiMedis AG Brief description: Together with OM (manager of “Gesundes Kinzigtal”(GK), a successfully operating population-based integrated care system (ICS) in Germany based on a shared benefits contract with health insurances, and of “Gesundheit für Billstedt/Horn”, another ICS, operating in a deprived municipal neighborhood) MRN is planning to implement a digitally integrated care management model for its 2.4 mil. inhabitants. For this, the area will be split into local regions of 100-150.000 inhabitants. Within each region local providers and patients will be connected using an electronic health record (eHR), the population will be activated and the care provision will be managed inter-sectoral and evidence based. On the metropolitan level these regions will be linked together and provided with central knowledge and services. The overall goal is to establish a highly qualitative and efficient prevention and care provision for the entire metropolitan area and thus increase its attractiveness and position it as a leading European health region for innovation and a test bed for medical research and implementation. The Project would be Germany’s first area-covering population-oriented integrated care of its size. Project Title: PEAIHD Brief description: Avergen Pharmaceuticals has identified small molecules that inhibit aggregation of mutated huntingtin (mHtt) at concentrations 400 nM in a cell-based Huntington’s disease (HD) model. Previously, several research groups have shown in mouse models that mHtt aggregation plays a pivotal role in HD. HD is a fatal autosomal dominant orphan drug indication with no disease modifying therapies available. In this in vivo efficacy study, Avergen Pharmaceuticals wants to demonstrate that the early lead compound can inhibit the aggregation of mutated huntingtin and that the inhibition of aggregation consecutively leads to an improvement of motor symptoms in the R6/2 Huntington’s disease model. This proof of efficacy of the early lead compound will be the bases to acquire series A investment and build a team to progress the project further. Project Title: neolexon for Kids Name of Organisation: neolexon UG i. G. Brief description: neolexon is bringing digitization to the domain of Speech and Language Therapy (SLT) in order to support therapists and patients. SLT aims to improve speech and language abilities, which are either lost due to a brain injury (called Aphasia) or not sufficiently developed as in the case of children. So far, SLT is severely dependent on analogue methods involving picture cards and memory games, which have a variety of disadvantages. neolexon aims to digitize this ecosystem in the form of tablet based apps supported by a handcrafted and medically reliable database. Using the neolexon system, therapists can easily create individual training materials out of a large set of words together with SLT relevant linguistic properties. The training materials are sent to target group-specific training apps in order to enable unlimited training at home. neolexon has so far built a comprehensive German word database and apps for adults effected with Aphasia. In its next steps, neolexon is building apps catering to children thereby establishing an extensive and commercially viable digital SLT solution. Project Title: Implementation of an IT infrastructure for improved medical research Name of Organisation: Climedo Health GmbH Brief description: Climedo supports the research activity at hospitals by providing doctors with an intelligent software solution to efficiently collect, archive and visualize clinical and biomedical data throughout their research process. Current inefficient management of medical research data in university hospitals, mainly caused by a lack of IT infrastructure, leads to massive losses in quality, time and money. European hospitals need to be fully equipped with smart systems in order to better support doctors in their difficult judgements regarding the interpretation of medical research outcomes. This will ultimately lead to more effective therapies. In the scope of the EIT Health grant, Climedo will conduct a customer-centric software development project at a well-known German university hospital to enable them conduct their research projects more effectively and efficiently. Project Title: Evolution of the Cancer Drug Efficacy CTR-Test® to Promote International Commercialization Name of Organisation: TherapySelect Dr. Frank Kischkel Brief description: Only 25% of cancer patients respond to their applied chemotherapy. To address this problem the CTR-Test (Chemotherapy-Resistance-Test) was developed. The test is a laboratory derived test and can measure efficacy of chemotherapeutic drugs on living tumor samples to find the best chemotherapy option for an individual cancer patient. Currently the test is commercially and exclusively offered by TherapySelect. The technology is ready to be out-licensed to other laboratories, but the biggest obstacle for an international commercialization is the usage of radioactivity. Thus within this project the current radioactivity-using CTR-Test version is modified that no radioactivity is needed anymore. In addition the high comparability between the current and modified version is ensured to fulfill all legal requirements for commercialization by performing a direct side-by-side comparison of both versions analyzing patients' tumor samples. With this project more cancer patients in Europe and worldwide can benefit from better treatment outcomes, resulting in prolonged life and better quality of life by reducing side effects of ineffective therapies. Reducing ineffective therapies also helps to reduce costs in the healthcare system. Thus our project addresses future challenges of healthcare due to aging societies, demographic change and contributes to the promotion of healthy living, well-being and improvement of healthcare. Active aging is also supported because cancer patients are treated with a more effective therapy. This leads to a higher chance that they recover, stay progression free and do not suffer from limitations caused by their cancer. The next chance for German or Swiss start-ups and SMEs to apply for the EIT Head Start funding will be in spring 2018. The new Head Start call is expected to be published at the end of the year. About the EIT The European Institute of Innovation & Technology (EIT) is an independent body of the European Union set up in 2008 to spur innovation and entrepreneurship across Europe. The EIT brings together leading higher education institutions, research labs and companies to form dynamic cross-border partnerships – Knowledge and Innovation Communities - that develop innovative products and services, start new companies, and train a new generation of entrepreneurs. The innovation communities are also tasked with overcoming some of the greatest challenges our society faces, including climate change, the use of raw materials, energy and active ageing. How do the innovation communities do this? See their own pages at the ' EIT Community ' link above to find out more.

NevisQ Frequently Asked Questions (FAQ)

  • When was NevisQ founded?

    NevisQ was founded in 2016.

  • Where is NevisQ's headquarters?

    NevisQ's headquarters is located at Dennewartstrasse 25-27, Aachen.

  • What is NevisQ's latest funding round?

    NevisQ's latest funding round is Incubator/Accelerator.

  • Who are the investors of NevisQ?

    Investors of NevisQ include Data Market Services, EIT Health Innostars and Qvartz.

  • Who are NevisQ's competitors?

    Competitors of NevisQ include Nymbl Science, Vayyar, EchoCare Technologies, Nobi Smart Lamps, SafelyYou and 16 more.

Compare NevisQ to Competitors

CarePredict Logo

CarePredict offers an AI-powered solution that detects changes in user's daily activities and behavior patterns that are precursors to health conditions in seniors.


UnaliWear is a maker of a Personal Emergency Response System (PERS) watch. UnaliWear provides the Kanega watch, which provides support for falls, medication reminders, and a guard against wandering, and features a use speech interface rather than buttons. The company combines cellular, Wi-Fi, GPS, BLE (for hearing aids and telemedicine devices), an accelerometer for automatic fall detection, and continuous speech to provide an active medical alert that works anywhere, along with artificial intelligence that learns the wearer's lifestyle to provide predictive, pre-emptive support.


GaitBetter provides motor-cognitive training for senior citizens. It utilizes virtual reality and treadmills to give physical training to seniors with restrained mobility.


Chirp offers peace of mind through non-wearable sensing that is less invasive than camera monitoring. The company's mission is to create a safer home for aging adults.

SafelyYou Logo

SafelyYou offers results-driven technology designed for fall prevention in memory care. Its AI-enabled video paired with support from SafelyYou means falls no longer go unwitnessed, root cause of falls can be identified, and future falls can be prevented. Its AI-enabled cameras are installed in the bedrooms of consenting residents, detecting falls without the need for sensors or action from the resident. It alerts on-site staff when a fall is detected. It offers a web portal, SafelyYou-Discover, where staff can review fall video to determine the root cause.

Zibrio Logo

Zibrio, fka iShoe, products measure and track balance, enabling people to make better health choices and achieve the independence they desire as they age. Zibrio uses advanced biometrics, commercializing NASA technology originally used on astronauts returning from space.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.